tiprankstipranks
Advertisement
Advertisement

OCS Stock Latest News

Oculis Advances Privosegtor Into Phase 3 Optic Neuritis Trial: What Investors Should Watch
Company AnnouncementsOculis Advances Privosegtor Into Phase 3 Optic Neuritis Trial: What Investors Should Watch
4d ago
OCS
Oculis Updates Investor Presentation, Emphasizing Late-Stage Neuro-Ophthalmic Pipeline and Cash Runway
PremiumCompany Announcements
Oculis Updates Investor Presentation, Emphasizing Late-Stage Neuro-Ophthalmic Pipeline and Cash Runway
10d ago
6K
OCS
Oculis price target lowered to $23 from $42 at JPMorgan
PremiumThe Fly
Oculis price target lowered to $23 from $42 at JPMorgan
1M ago
OCS
Oculis price target lowered to $38 from $49 at Baird
PremiumThe Fly
Oculis price target lowered to $38 from $49 at Baird
1M ago
OCS
Oculis price target lowered to $38 from $49 at Baird
PremiumThe Fly
Oculis price target lowered to $38 from $49 at Baird
1M ago
OCS
Video: Nvidia rallies after taking wraps off new PC processor
PremiumThe FlyVideo: Nvidia rallies after taking wraps off new PC processor
1M ago
AMD
OCS
Oculis price target lowered to $35 from $44 at BofA
Premium
The Fly
Oculis price target lowered to $35 from $44 at BofA
1M ago
OCS
Oculis price target lowered to $38 from $46 at Needham
Premium
The Fly
Oculis price target lowered to $38 from $46 at Needham
1M ago
OCS
Oculis price target lowered to $45 from $75 at Guggenheim
PremiumThe Fly
Oculis price target lowered to $45 from $75 at Guggenheim
1M ago
OCS
Oculis price target lowered to $26 from $47 at H.C. Wainwright
PremiumThe Fly
Oculis price target lowered to $26 from $47 at H.C. Wainwright
1M ago
OCS
Oculis price target lowered to $40 from $50 at Stifel
PremiumThe Fly
Oculis price target lowered to $40 from $50 at Stifel
1M ago
OCS
Oculis Maintained at Buy as Analyst Lowers Price Target to $45, Refocuses on Optic Neuritis Opportunity
PremiumRatings
Oculis Maintained at Buy as Analyst Lowers Price Target to $45, Refocuses on Optic Neuritis Opportunity
1M ago
OCS
Analyst Maintains Buy on Oculis, Sees Upside Driven by Optic Neuropathy and Dry Eye Pipelines Despite OCS-01 Phase 3 Setback
PremiumRatingsAnalyst Maintains Buy on Oculis, Sees Upside Driven by Optic Neuropathy and Dry Eye Pipelines Despite OCS-01 Phase 3 Setback
1M ago
OCS
Oculis Holding AG trading resumes
Premium
The Fly
Oculis Holding AG trading resumes
1M ago
OCS
Oculis reports primary endpoint of DIAMOND Phase 3 trials was not met
Premium
The Fly
Oculis reports primary endpoint of DIAMOND Phase 3 trials was not met
1M ago
OCS
Oculis Holding AG trading halted, news pending
PremiumThe Fly
Oculis Holding AG trading halted, news pending
1M ago
OCS
Oculis quickly falls 26% to $22 per share
PremiumThe Fly
Oculis quickly falls 26% to $22 per share
1M ago
OCS
Etsy upgraded, ZoomInfo downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Etsy upgraded, ZoomInfo downgraded: Wall Street’s top analyst calls
2M ago
KD
RM
Oculis initiated with a Buy at Guggenheim
PremiumThe Fly
Oculis initiated with a Buy at Guggenheim
2M ago
OCS
Oculis price target raised to $42 from $38 at JPMorgan
PremiumThe FlyOculis price target raised to $42 from $38 at JPMorgan
2M ago
OCS
Oculis AGM Backs All Proposals, Adds Veteran Biotech CFO to Board and Expands Capital Flexibility
Premium
Company Announcements
Oculis AGM Backs All Proposals, Adds Veteran Biotech CFO to Board and Expands Capital Flexibility
2M ago
6K
OCS
Oculis price target raised to $47 from $44 at H.C. Wainwright
Premium
The Fly
Oculis price target raised to $47 from $44 at H.C. Wainwright
2M ago
OCS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >